Search

Displaying results 2761 - 2770 of 4262 in total
  1. Drug

    Human interferon beta

    go.drugbank.com/drugs/DB14999
    ApprovedInvestigational

    Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992.

  2. Drug

    Lysine

    go.drugbank.com/drugs/DB00123
    ApprovedInvestigationalNutraceutical

    Collagen contains hydroxylysine which is derived from lysine by lysyl hydroxylase.

  3. Drug

    Glymidine

    go.drugbank.com/drugs/DB01382
    Approved

    Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin.

  4. Drug

    Medrysone

    go.drugbank.com/drugs/DB00253
    Approved

    Medrysone is a corticosteroid used in ophthalmology.

  5. Drug

    Isoniazid

    go.drugbank.com/drugs/DB00951
    ApprovedInvestigational

    Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

  6. Drug

    Cyclopentolate

    go.drugbank.com/drugs/DB00979
    Approved

    A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.

  7. Drug

    Aminophenazone

    go.drugbank.com/drugs/DB01424
    ApprovedWithdrawn

    Aminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis. In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to ...

  8. Drug

    CP-122721

    go.drugbank.com/drugs/DB05421
    Experimental

    CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.

  9. Drug

    Nigericin

    go.drugbank.com/drugs/DB14056
    Experimental

    It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed)

  10. Drug

    REC-994

    go.drugbank.com/drugs/DB15616
    Investigational

    REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).